Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more
Shandong Xinhua Pharmaceutical Company Limited (SHNXY) - Total Assets
Latest total assets as of June 2025: $9.24 Billion USD
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (SHNXY) holds total assets worth $9.24 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Xinhua Pharmaceutical Company Limited - Total Assets Trend (2018–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Xinhua Pharmaceutical Company Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Xinhua Pharmaceutical Company Limited's total assets of $9.24 Billion consist of 41.3% current assets and 58.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.8% |
| Accounts Receivable | $868.20 Million | 9.6% |
| Inventory | $1.27 Billion | 14.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $565.04 Million | 6.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Xinhua Pharmaceutical Company Limited's current assets represent 41.3% of total assets in 2024, an increase from 39.7% in 2018.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2024, up from 13.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 14.1% of total assets.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Total Assets
Key competitors of Shandong Xinhua Pharmaceutical Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shandong Xinhua Pharmaceutical Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Shandong Xinhua Pharmaceutical Company Limited generates 0.94x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shandong Xinhua Pharmaceutical Company Limited generates $5.21 in net profit.
Shandong Xinhua Pharmaceutical Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.39 | 1.12 |
| Quick Ratio | 0.88 | 0.94 | 0.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $839.89 Million | $ 1.02 Billion | $ 293.59 Million |
Shandong Xinhua Pharmaceutical Company Limited - Advanced Valuation Insights
This section examines the relationship between Shandong Xinhua Pharmaceutical Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.13 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | $9.02 Billion |
| Market Capitalization | $2.00 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Xinhua Pharmaceutical Company Limited's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Xinhua Pharmaceutical Company Limited's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Xinhua Pharmaceutical Company Limited (2018–2024)
The table below shows the annual total assets of Shandong Xinhua Pharmaceutical Company Limited from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.02 Billion | +8.85% |
| 2023-12-31 | $8.29 Billion | +0.26% |
| 2022-12-31 | $8.26 Billion | +12.72% |
| 2021-12-31 | $7.33 Billion | +3.37% |
| 2020-12-31 | $7.09 Billion | +10.21% |
| 2019-12-31 | $6.44 Billion | +8.79% |
| 2018-12-31 | $5.92 Billion | -- |